

## Midterm Review 2005

### **Pharmacokinetics- “what the body does to the drug”**

- Absorption, Distribution, Metabolism, Excretion
- Described by graph of plasma concentration over time  $\rightarrow t_{1/2}$ ,  $k$ ,  $V_d$ , AUC

### **Pharmacodynamics- “what the drug does to the body”**

- Related to receptor-target interactions, both binding and downstream signaling
- Described graph of response versus dose  $\rightarrow$  potency, efficacy

### **\*\*Understand your graphs and what they signify!**

\*\*\*\*\*

For each lecture topic,

- \* **Draw a pathway that explains underlying (patho)physiology and potential targets**
- \* **Identify drugs that target the pathway** (net positive or negative effect?)
- \* Special therapeutic principles

\*\*\*\*\*

For all drugs,

- \* **Mechanism of action**
- \* **What does it treat?**

If pertinent,

1. Selectivity (receptor selectivity; other means for conferring selectivity)
2. Toxicity... many examples
3. Reversible versus irreversible inhibition (AChE inhibitors, aspirin versus other NSAIDS)
4. Absorption (administration of epinephrine to minimize absorption of lidocaine)
5. Distribution (digoxin, anesthetics redistribution as a mechanism of clearance)
6. Metabolism (toxic metabolites, pro-drug activation)
7. Elimination (dosing for renal/hepatic failure, later in 2<sup>nd</sup> half of course phenytoin example of 0-order elimination)
8. Monitoring: does plasma drug levels correlate with efficacy and/or toxicity? (warfarin, digoxin)

\*\*\*\*\*

### **Therapeutics**

When actually administering drugs to patients, the following may apply:

- Drug combination therapy

*Examples:* examples to come in antibiotics

- Drug interactions, especially in drug metabolism  
*Examples:* Effect on warfarin metabolism of P450 inducers and inhibitors; MAO inhibitors and tyramine
- Mode of administration  
*Examples:* Inhalation of asthma drugs; topical administration of glaucoma drugs
- Order of administration  
*Examples:* thioamides before iodides in Rx of hyperthyroidism;  $\alpha$ -blocker before  $\beta$ -blocker in Rx of pheochromocytoma; for gout if high uric acid load, allopurinol to stop synthesis before probenecid
- Drug resistance  
*Examples:* many in antibiotics and chemotherapeutics next section of course

Think of examples when these concepts might be important as you review.

\*\*\*\*\*

### ***Case presentations***

#### Anticholinesterase

- Direct versus indirect agonists (targets receptor directly versus affects binding/signaling)
- Symptoms/signs and treatment of toxicity

#### Anticoagulation

- Concept of therapeutic window, specifically *narrow* therapeutic window of warfarin → need for close monitoring and attention to anything that would effect drug levels
- Drug interactions, both inducer and inhibitor of drug metabolism

#### Sulfasalazine

- Use of pro-drug sulfapyridine
- Side effects of metabolized pro-drug
- Decreased bioavailability and usefulness in therapeutic effect

#### Pheochromocytoma

- Acute versus long-term treatment
- Order of treatment:  $\alpha$ -blocker then  $\beta$ -blocker

#### Asthma

- Strategy for treatment: bronchodilation versus anti-inflammatory; acute versus chronic
- Toxicity associated with theophylline

#### Poison Control

- Mechanism for antidote

## Glaucoma

- Open vs closed angle glaucoma and treatment
- Mechanism of Rx and drugs: 1) reduce fluid production and 2) increase drainage

## Pharmacogenetics

- CYP2D6 polymorphism
- Drug metabolism: active → inactive, pro-drug → active, active → toxic

## Thyroid Disease

- Thyroid hormone biosynthesis and therapeutic targets
- Order of administration: thioamides before iodide

## Cocaine

- Mechanism of action: NE reuptake inhibition, local anesthetic, DA reuptake inhibition (CNS)
- CV effects: coronary vasospasm, sympathetic overload

## Gout

- Etiology of uric acid overload (“wine and meat,” tumor lysis syndrome, drugs, etc) and pathophysiology of crystal deposition and inflammation
- Acute anti-inflammatory therapy versus chronic reversal of hyperuricemia
- Toxicity of colchicines

\*\*\*\*\*

## Lecture Topics- Special Notes

### Dose-Response/ Drug-Receptor Interactions- Strichartz

1. Effect of spare receptors on  $K_{ap}$  of competitive agonist? Antagonist?
2. Full agonists vs partial agonists vs antagonists
3. Reversible vs irreversible antagonist (effect on dose response curves)

### Pharmacokinetics- Walsh

1. Be able to calculate bioavailability
2. Effect of absorption, distribution, and clearance on therapeutic efficacy

### Drug delivery- Langer

1. Sustained vs controlled vs targeted release (how to achieve)
2. When is each type of release kinetics desired?

### Drug Metabolism/ Pharmacogenetics- Dershwitz

1. G6PD deficiency and mechanism for inducing adverse reaction
2. Pseudocholinesterase
3. Porphyria
4. Fast vs slow acetylators

### Autonomic Pharmacology- Stichartz/ Rosow

1. Difference between depolarizing and non-depolarizing muscle relaxants (fasciculations, fade, reversal of block with AchE inhibitors, post-tetanic potentiation)
2. Difference between nicotinic vs muscarinic receptors
3. How do nicotinic receptors work (aka Na channel)
4. G-protein coupled muscarinic receptors: which are stimulatory, which inhibitory
5. Mechanisms for down-regulating  $\beta$ -adrenergic signaling (tachyphylaxis, receptor downregulation, receptor endocytosis, desensitivation via phosphorylation)
6. Advantage of selective  $\alpha$ 1-receptor antagonist over nonselective  $\alpha$ -blocker

### Local Anesthetics- Strichartz

1. Effect of protonated drugs on membrane permeability and Na channel binding
2. Use-dependent blockade
3. Why bicarbonate and epinephrine co-administered with lidocaine

### Anti-dysrhythmics- Ruskin

1. Effect of different classes on myocardial action potential and automaticity
2. Toxicity of Class III (Torsades de pointes) from prolonged QT
3. Selectivity of class I and IV from use-dependent blockade of channels
4. Acute vs long-term management of arrhythmias

### Anti-inflammatory drugs- Weinblatt

1. NSAID toxicity
2. Aspirin effect on platelets (why? Because of irreversible inhibition!)

### Drugs for CHF- Baker

1. Which drug classes proven to have mortality benefit?
2. Rationale for using  $\beta$ -agonists in short-term and  $\beta$ -antagonists in long-term management

### Drugs for hypertension- Baker

1. Different classes of drugs, diuretics, sympatholytics, vasodilators, rennin-angiotensin blockers and mechanism for lowering pressures
2. Combining different classes for synergistic effect

### Lipid-lowering drugs- Lees

1. Effect of statins on LDL receptors and ultimately level of plasma LDL
2. Niacin toxicity